Author name: Leonardo Arias

Nearly one-third of biotech and pharma professionals are thinking about leaving the U.S. to find biopharma jobs, according to a BioSpace LinkedIn poll. Career coaches discuss why people are considering relocating and what they should do before heading for the exit.

Generic versions of biologic drugs could hit the market without human trials and allow the market forces to bring down costs, HHS leaders said while announcing new draft guidance.

Descubre cómo la analítica de video con IA está redefiniendo la seguridad urbana — ejemplos reales, productos destacados y prácticas éticas para una implementación efectiva.   Seamos honestos: las ciudades actuales son más complejas que n …

The healthcare giant beat Wall Street expectations in the third quarter, but reported a net loss after recording a $5.7 billion charge linked primarily to decelerating clinic growth at Oak Street Health.

National Medicare coverage paves the way for a larger patient population to access the blood pressure treatment, which gained FDA approval in 2023.

Late-breaking Phase III data show ianalumab, Novartis’ dual-targeted antibody, reduced disease activity and patient burden in Sjögren’s disease, the pharma reported at the American College of Rheumatology Convergence congress on Wednesday.

More than 60% of respondents said insurance companies are most at fault for medical debt, compared with just 9% who blamed hospitals, according to a survey by nonprofit Undue Medical Debt.

The purchase is expected to complement Thermo’s clinical research services, as companies are conducting more clinical trials.

Genentech is letting go of 118 employees in San Francisco. The news comes about two months after the biotech ended a partnership with Adaptive Biotechnologies.

The operator increased its outlook after posting earnings growth in the third quarter, aided by strong demand for services in its acute business and a newly approved Medicaid state supplemental payment program.